FDA 483 - ImpactLife - July 03, 2025

Between June 30 and July 3, 2025, the U.S. Food and Drug Administration (FDA) conducted an inspection of ImpactLife, a community blood bank located in Urbana, Illinois. The inspection revealed significant deficiencies in the facility's management of donor safety and reporting protocols. The primary violation involves the failure to maintain complete written reports and conduct thorough investigations into adverse reactions experienced by donors. Although the company's internal procedures require documentation of such events, investigators identified multiple instances where severe reactions were recorded without essential details, such as donor symptoms or the specific medical treatment provided. Furthermore, the facility failed to initiate formal adverse event reports following donor complaints regarding post-donation issues, including severe bruising, pain, and loss of consciousness. These findings were issued under the regulatory framework of the Federal Food, Drug, and Cosmetic Act. While this document is not a final determination of compliance, ImpactLife is required to respond to the FDA with a detailed plan for corrective actions or provide objections to the findings to ensure the safety and integrity of its donor programs.